| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $535,647 | 3 | 75 |
Sells | $121,220 | 1 | 25 |
| RAMSAY DAVID A | director | 1 | $416,250 | 1 | $121,220 | $295,030 |
| Hawkins Richard J | director | 1 | $98,572 | 0 | $0 | $98,572 |
| McCracken Joseph S | director | 1 | $20,825 | 0 | $0 | $20,825 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Over the last 12 months, insiders at Savara Inc. have bought $535,647 and sold $121,220 worth of Savara Inc. stock.
On average, over the past 5 years, insiders at Savara Inc. have bought $2.75M and sold $343,772 worth of stock each year.
Highest buying activity among insiders over the last 12 months: RAMSAY DAVID A (director) — $416,250. Hawkins Richard J (director) — $98,572. McCracken Joseph S (director) — $20,825.
The last purchase of 48,225 shares for transaction amount of $98,572 was made by Hawkins Richard J (director) on 2025‑06‑20.
| 2025-12-19 | Sale | RAMSAY DAVID A | director | 20,000 0.0098% | $6.06 | $121,220 | -5.00% | |
| 2025-06-20 | Hawkins Richard J | director | 48,225 0.0277% | $2.04 | $98,572 | +100.00% | ||
| 2025-05-29 | McCracken Joseph S | director | 10,000 0.0054% | $2.08 | $20,825 | +71.88% | ||
| 2025-03-31 | RAMSAY DAVID A | director | 150,000 0.0876% | $2.77 | $416,250 | +25.99% | ||
| 2024-12-16 | Sale | Pauls Matthew | CHIEF EXECUTIVE OFFICER | 54,702 0.0322% | $3.31 | $180,828 | -8.59% | |
| 2024-12-16 | Sale | Lowrance David L | Chief Financial Officer | 25,000 0.0148% | $3.33 | $83,278 | -8.59% | |
| 2024-12-16 | Sale | Hawkins Richard J | director | 8,000 0.0047% | $3.32 | $26,569 | -8.59% | |
| 2024-11-19 | McCracken Joseph S | director | 20,000 0.0117% | $2.95 | $59,072 | +1.36% | ||
| 2024-11-18 | RAMSAY DAVID A | director | 100,000 0.0566% | $2.88 | $287,600 | -0.17% | ||
| 2023-12-28 | Sale | Pauls Matthew | CHIEF EXECUTIVE OFFICER | 84,000 0.0609% | $4.71 | $395,900 | -9.75% | |
| 2023-12-28 | Sale | Lowrance David L | CHIEF FINANCIAL OFFICER | 10,000 0.0072% | $4.71 | $47,131 | -9.75% | |
| 2023-12-28 | Sale | Elam Nevan C | director | 93,843 0.068% | $4.71 | $442,291 | -9.75% | |
| 2023-07-17 | Yang Rick | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Walker Paul Edward | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | SANDELL SCOTT D | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Mathers Edward T | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Makhzoumi Mohamad | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Growth Equity Opportunities 17, LLC | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Florence Anthony A. Jr. | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% | ||
| 2023-07-17 | Chang Carmen | 10 percent owner | 333,333 0.2084% | $3.00 | $999,999 | +32.80% |
| RAMSAY DAVID A | director | 2533642 1.2452% | $14.21M | 53 | 1 | +45.52% |
| McCracken Joseph S | director | 260837 0.1282% | $1.46M | 4 | 0 | +20.02% |
| Hawkins Richard J | director | 115466 0.0567% | $647,764.26 | 1 | 3 | |
| SANDELL SCOTT D | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| BASKETT FOREST | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| Mathers Edward T | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| Walker Paul Edward | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| Florence Anthony A. Jr. | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| Behbahani Ali | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| Makhzoumi Mohamad | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| Chang Carmen | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| Growth Equity Opportunities 17, LLC | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| Yang Rick | 10 percent owner | 24471264 12.0271% | $137.28M | 1 | 0 | +32.8% |
| LEVINE EVAN | CEO & President | 4395000 2.16% | $24.66M | 13 | 7 | |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER | 1536379 0.7551% | $8.62M | 10 | 2 | <0.0001% |
| EMANUELE ROBERT MARTIN | Senior VP, Development | 547663 0.2692% | $3.07M | 0 | 1 | |
| Neville Robert N | Chief Executive Officer | 498028 0.2448% | $2.79M | 2 | 4 | +85.25% |
| Lowrance David L | Chief Financial Officer | 381005 0.1873% | $2.14M | 3 | 12 | +23.24% |
| Chowdhury Badrul A. | CHIEF MEDICAL OFFICER | 175000 0.086% | $981,750.00 | 1 | 1 | +24.29% |
| Jouhikainen Jaakko Taneli | President and COO | 167569 0.0824% | $940,062.09 | 1 | 7 | +85.25% |
| Pratt Raymond Dennis | Chief Medical Officer | 160000 0.0786% | $897,600.00 | 2 | 0 | +81.8% |
| PIKOVER YURI | director | 153734 0.0756% | $862,447.74 | 3 | 0 | +39.18% |
| Roberts Brandi | Chief Financial Officer & SVP | 38000 0.0187% | $213,180.00 | 2 | 0 | |
| MERRITT JAMES A | President & Chf Med Officer | 35000 0.0172% | $196,350.00 | 1 | 0 | |
| Culley Brian M | CEO and Director | 34500 0.017% | $193,545.00 | 3 | 1 | |
| Elam Nevan C | director | 22500 0.0111% | $126,225.00 | 0 | 1 | |
| ROBBINS JOAN M | CSO, Sr. VP | 10000 0.0049% | $56,100.00 | 2 | 2 | |
| PYKETT MARK JEROME | director | 8000 0.0039% | $44,880.00 | 1 | 0 |
$607,159,124 | 92 | 3.55% | $1.05B | |
$100,473,344 | 83 | 9.53% | $1.41B | |
Savara Inc. (SVRA) | $14,874,415 | 78 | 37.43% | $1.14B |
$613,304,943 | 46 | 11.85% | $1.33B | |
$150,336,897 | 29 | -5.97% | $1.08B | |
$104,199,091 | 28 | 16.42% | $1.09B | |
$121,322,364 | 24 | -6.74% | $1.28B | |
$276,750,010 | 16 | -7.95% | $1.13B | |
$21,945,105 | 15 | -26.51% | $1.09B | |
$144,557,026 | 13 | 0.49% | $1.24B | |
$278,247,340 | 12 | 58.08% | $1.38B | |
$49,967,154 | 11 | 62.08% | $1.25B | |
$1,435,760 | 10 | 2.01% | $1.04B | |
$117,959,652 | 9 | -12.47% | $1.3B | |
$1,944,616 | 6 | 0.35% | $1.09B | |
$19,420,853 | 5 | 4.35% | $1.26B | |
$25,999,974 | 4 | 0.00% | $1.05B | |
$33,624,000 | 2 | -50.37% | $1.1B | |
$173,869 | 1 | 29.48% | $1.26B |
| Increased Positions | 99 | +81.82% | 56M | +34.55% |
| Decreased Positions | 54 | -44.63% | 16M | -9.63% |
| New Positions | 47 | New | 32M | New |
| Sold Out Positions | 14 | Sold Out | 3M | Sold Out |
| Total Postitions | 166 | +37.19% | 202M | +24.92% |
| Nea Management Company, Llc | $138,018.00 | 12.06% | 24.47M | 0 | 0% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $99,268.00 | 8.67% | 17.6M | 0 | 0% | 2025-09-30 |
| Vr Adviser, Llc | $71,521.00 | 6.25% | 12.68M | +4M | +42.74% | 2025-09-30 |
| Tcg Crossover Management, Llc | $69,723.00 | 6.09% | 12.36M | 0 | 0% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $64,647.00 | 5.65% | 11.46M | 0 | 0% | 2025-09-30 |
| Nantahala Capital Management, Llc | $49,493.00 | 4.32% | 8.78M | +450,000 | +5.41% | 2025-09-30 |
| Blackrock, Inc. | $47,648.00 | 4.16% | 8.45M | -1M | -13.58% | 2025-09-30 |
| Vanguard Group Inc | $46,886.00 | 4.1% | 8.31M | -140,786 | -1.67% | 2025-09-30 |
| Deerfield Management Company, L.P. | $44,917.00 | 3.92% | 7.96M | 0 | 0% | 2025-09-30 |
| Vestal Point Capital, Lp | $22,645.00 | 1.98% | 4.01M | -7M | -63.55% | 2025-09-30 |